JP2023501745A5 - - Google Patents

Info

Publication number
JP2023501745A5
JP2023501745A5 JP2022528582A JP2022528582A JP2023501745A5 JP 2023501745 A5 JP2023501745 A5 JP 2023501745A5 JP 2022528582 A JP2022528582 A JP 2022528582A JP 2022528582 A JP2022528582 A JP 2022528582A JP 2023501745 A5 JP2023501745 A5 JP 2023501745A5
Authority
JP
Japan
Prior art keywords
antigen
pharmaceutical composition
hypercholesterolemia
binding fragment
ldl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022528582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501745A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/129763 external-priority patent/WO2021098720A1/zh
Publication of JP2023501745A publication Critical patent/JP2023501745A/ja
Publication of JP2023501745A5 publication Critical patent/JP2023501745A5/ja
Priority to JP2025133754A priority Critical patent/JP2025172265A/ja
Pending legal-status Critical Current

Links

JP2022528582A 2019-11-18 2020-11-18 抗ｐｃｓｋ９抗体及びその使用 Pending JP2023501745A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025133754A JP2025172265A (ja) 2019-11-18 2025-08-08 抗ｐｃｓｋ９抗体及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201911132974.4 2019-11-18
CN201911132974 2019-11-18
CN201911133187 2019-11-18
CN201911133187.1 2019-11-18
PCT/CN2020/129763 WO2021098720A1 (zh) 2019-11-18 2020-11-18 抗pcsk9抗体及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025133754A Division JP2025172265A (ja) 2019-11-18 2025-08-08 抗ｐｃｓｋ９抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2023501745A JP2023501745A (ja) 2023-01-18
JP2023501745A5 true JP2023501745A5 (https=) 2023-11-21

Family

ID=75853278

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022528582A Pending JP2023501745A (ja) 2019-11-18 2020-11-18 抗ｐｃｓｋ９抗体及びその使用
JP2025133754A Pending JP2025172265A (ja) 2019-11-18 2025-08-08 抗ｐｃｓｋ９抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025133754A Pending JP2025172265A (ja) 2019-11-18 2025-08-08 抗ｐｃｓｋ９抗体及びその使用

Country Status (12)

Country Link
US (1) US20230312750A1 (https=)
EP (1) EP4063396A4 (https=)
JP (2) JP2023501745A (https=)
KR (1) KR20220107210A (https=)
CN (1) CN112812188A (https=)
AU (1) AU2020388182A1 (https=)
BR (1) BR112022009587A2 (https=)
CA (1) CA3160071A1 (https=)
IL (2) IL292973B2 (https=)
MX (1) MX2022005959A (https=)
PH (1) PH12022551172A1 (https=)
WO (1) WO2021098720A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025522576A (ja) * 2022-06-30 2025-07-15 エーディー ファーマシューティカルズ カンパニー，リミティド 抗ｐｃｓｋ９抗体製剤及びその応用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
NZ584902A (en) * 2007-10-26 2012-03-30 Schering Corp Anti-pcsk9 and methods for treating lipid and cholesterol disorders
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TWI682780B (zh) * 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
ES2914978T3 (es) * 2013-10-11 2022-06-20 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
CA2955304C (en) * 2014-07-16 2023-12-12 Sanofi Biotechnology Methods for treating high cardiovascular risk patients with hypercholesterolemia
KR20230074283A (ko) * 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
CN105461809B (zh) * 2015-02-11 2018-10-12 康融东方（广东）医药有限公司 Pcsk9抗体、其药物组合物及其用途
EA039310B1 (ru) * 2015-02-26 2022-01-12 Санофи Байотекнолоджи Способы снижения сердечно-сосудистого риска
CN108239150A (zh) * 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途

Similar Documents

Publication Publication Date Title
JP7404471B2 (ja) 家族性高コレステロール血症を有する患者を処置するための方法
TWI705826B (zh) 特異性結合pcsk9之單株抗體用於治療或預防膽固醇相關疾病之用途
JP2019514907A5 (https=)
CN118105481A (zh) 用于与pcsk9抑制剂一起使用的给药方案
US20240197870A1 (en) Methods for treating patients with refractory hypercholesterolemia
JP2023501745A5 (https=)
JP2025172265A (ja) 抗ｐｃｓｋ９抗体及びその使用
JP2023506732A (ja) ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用
WO2021185344A1 (zh) 一种胆固醇相关疾病的治疗方法
EA049226B1 (ru) Анти-pcsk9 антитело и его применение
HK40003056A (en) Methods for treating patients with familial hypercholesterolemia
NZ717550B2 (en) Methods of treating or preventing cholesterol related disorders